Pasar al contenido principal

TERAPIAS RNAI CARDIOSELECTIVAS TRASLACIONALES Y CORAZON-EN-CHIP PREDICTIVOS PARA ABORDAR LOS DESAFIOS CLINICOS CARDIACOS

PID2022-139859OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE ZARAGOZA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

DNA-based nanocarriers to sequester altered microRNAs in cardiac dysfunction

  • Postigo, Alejandro
  • Hernández-Bellido, Natalia
  • Sánchez-Barat, Marcos
  • García-Mendívil, Laura
  • Pueyo, Esther
  • Barrio, Jesús del
  • Hernández-Ainsa, Silvia
  • Ordovás, Laura
MicroRNAs (miRs) play a critical role in modulating gene expression across biological processes, including cardiac aging and disease. As such, miRs have demonstrated therapeutic potential in several cardiac conditions. Efficient delivery of miR therapies to cardiac tissue is crucial for effective gene therapy and DNA-based nanocarriers (DNCs), based on Watson-Crick-Franklin highly specific base-pair recognition, have emerged as a promising, biocompatible alternative to viral-based methods. Here, DNCs designed to modulate miR levels as a potential treatment for cardiac dysfunction are presented. Specifically, the DNCs target miR-24-2, which inhibits SERCA2 gene. In humans, the reduction of SERCA2 activity is a hallmark of heart failure and is altered in cardiac aging. The assembled DNCs bearing anti-miR-24-2-5p sequences effectively restore intracellular levels of SERCA2 in a HEK293 cell model. The DNCs proper assembly is thoroughly verified, while their stability and miR-capture ability are demonstrated in vitro. The DNCs exhibit successful internalization into HEK293 and modest uptake into human cardiomyocytes. SERCA2 restoration by DNCs is significantly influenced by the miR-capture sequence layout, underscoring the importance of precise design for optimal biological outcomes. This study highlights the potential of DNCs in cardiac therapies, a previously unexplored avenue for addressing cardiac dysfunction., Authors acknowledge the following funding: grant LMP128_21 by Gobierno de Aragón, grant PID2020-113003GB-I00 funded by MICIU/AEI/10.13039/501100011033, PID2022-139859OB-I00 funded by MICIU/AEI/10.13039/501100011033 and ERDF, UE and Research Group grants (E47_23R and T39_23R) by Gobierno de Aragón. This study was also supported by MCIN with funding from European Union NextGenerationEU (PRTR-C17.I1). Authors also acknowledge DNABEATS project, Joint Transnational Call 2022 of M-ERA.NET 3, (Horizon 2020 grant agreement No 958174) and supported by grants PCI2023-143390 and PCI2023-143438 funded by MICIU/AEI/10.13039/501100011033 and cofounded by EU. N.H.-B. and M.S.-B. were funded by Gobierno de Aragón fellowships CPB_09_20 and CPB_14_22, respectively. The authors would like to acknowledge the Servicio General de Apoyo a la Investigación-SAI (Universidad de Zaragoza) and Servicios Científico-Técnicos (microscopía, UNATI, y citometría) of CIBA (IISA-IACS-Universidad de Zaragoza) for their support., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Nanotechnology-driven heart targeting to fulfil the potential of cardiac microRNA therapies

  • Hernández-Bellido, Natalia
  • Hernández-Ainsa, Silvia
  • Köhler, Ralf
  • Ordovás, Laura
MicroRNAs play a crucial role in regulating gene expression in most biological processes, including cardiac disease, regeneration and aging. They are therefore an attractive and novel therapeutic option, and extensive research in small animal models has demonstrated this potential in the heart. While the therapeutic outcomes obtained in large animal models are also promising, far fewer studies have been conducted in this species. Even fewer microRNA therapeutics have reached clinical trials, only CDR132L and MRG-110. This highlights a bottleneck in their development primarily associated with challenges in their in vivo delivery, specifically due to their limited stability and ability to penetrate the heart tissue., This review aims to describe the current state of development of cardiac microRNA therapies in relation to these challenges and to provide a comparative overview of the progress made in overcoming them. A special focus is set on the application of pharmaceutical nanotechnology and the development of targeted delivery strategies to the heart. These approaches have been tested primarily in small animal models and have shown to improve the cardiac penetration, accumulation and/or stability and of microRNAs and, therefore, their therapeutic efficacy compared to naked delivery. Notably, the latter is typically the method of choice in late preclinical research and early clinical trials. Consequently, targeted microRNA nanotherapies could be pivotal in overcoming the current bottleneck and realizing the therapeutic potential of microRNAs in the heart., In conclusion, this review offers an outlook of the future applicability of microRNA therapies leveraging the latest advances in non-viral targeted delivery with nanocarriers., LO acknowledges the support of grant PID2022-139859OB-I00 funded by MCIU/AEI/10.13039/501100011033 and ERDF, EU and grant PROY_B08_24 and BSICoS group T39_23R funded by Gobierno de Aragón. LO and SHA also acknowledge DNABEATS project, Joint Transnational Call 2022 of M-ERA.NET 3, (Horizon 2020 grant agreement No 958174) and supported by grants PCI2023-143390 and PCI2023-143438 funded by MICIU/AEI/10.13039/501100011033 and cofounded by EU. SHA acknowledges support by grant PID2023-147656OB-I00 funded by MICIU/AEI/10.13039/501100011033 and by ERDF, UE, and MCIN with funding from the European Union NextGenerationEU (PRTR-C17.I1) promoted by the Government of Aragón. N.H-B was supported by the predoctoral (CPB_09_20) and mobility (MVB_03_23) fellowships funded by Gobierno de Aragón., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Generation of Self-Induced Myocardial Ischemia in Large-Sized Cardiac Spheroids without Alteration of Environmental Conditions Recreates Fibrotic Remodeling and Tissue Stiffening Revealed by Constriction Assays

  • Paz-Artigas, Laura
  • González-Lana, Sandra
  • Polo, Nicolás
  • Vicente, Pedro
  • Montero-Calle, Pilar
  • Martínez, Miguel A.
  • Rábago, Gregorio
  • Serra, Margarida
  • Prósper, Felipe
  • Mazo, Manuel M.
  • González, Arantxa
  • Ochoa, Ignacio
  • Ciriza, Jesús
A combination of human-induced pluripotent stem cells (hiPSCs) and 3D microtissue culture techniques allows the generation of models that recapitulate the cardiac microenvironment for preclinical research of new treatments. In particular, spheroids represent the simplest approach to culture cells in 3D and generate gradients of cellular access to the media, mimicking the effects of an ischemic event. However, previous models required incubation under low oxygen conditions or deprived nutrient media to recreate ischemia. Here, we describe the generation of large spheroids (i.e., larger than 500 μm diameter) that self-induce an ischemic core. Spheroids were generated by coculture of cardiomyocytes derived from hiPSCs (hiPSC-CMs) and primary human cardiac fibroblast (hCF). In the proper medium, cells formed aggregates that generated an ischemic core 2 days after seeding. Spheroids also showed spontaneous cellular reorganization after 10 days, with hiPSC-CMs located at the center and surrounded by hCFs. This led to an increase in microtissue stiffness, characterized by the implementation of a constriction assay. All in all, these phenomena are hints of the fibrotic tissue remodeling secondary to a cardiac ischemic event, thus demonstrating the suitability of these spheroids for the modeling of human cardiac ischemia and its potential application for new treatments and drug research.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Analysis of age-related changes in the left ventricular myocardium with multiphoton microscopy

  • Bueno, Juan M.
  • Martínez-Ojeda, Rosa M.
  • Pérez-Zabalza, María
  • García-Mendívil, Laura
  • Asensio, M. Carmen
  • Ordovás, Laura
  • Pueyo, Esther
Aging induces cardiac remodeling, resulting in an increase in the risk of suffering heart diseases, including heart failure. Collagen deposition increases with age and, together with sarcomeric changes in cardiomyocytes, may lead to ventricular stiffness. Multiphoton (MP) microscopy is a useful technique to visualize and detect variations in cardiac structures in a label free fashion. Here, we propose a method based on MP imaging (both two-photon excitation fluorescence (TPEF) and second harmonic generation (SHG) modalities) to explore and objectively quantify age-related structural differences in various components of cardiac tissues. Results in transmural porcine left ventricle (LV) sections reveal significant differences when comparing samples from young and old animals. Collagen and myosin SHG signals in old specimens are respectively 3.8x and >6-fold larger than in young ones. Differences in TPEF signals from cardiomyocyte were ∼3x. Moreover, the increased amount of collagen in old specimens results in a more organized pattern when compared to young LV tissues. Since changes in collagen and myosin are associated with cardiac dysfunction, the technique used herein might be a useful tool to accurately predict and measure changes associated with age-related myocardium fibrosis, tissue remodeling and sarcomeric alterations, with potential implications in preventing heart disease.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

DNA-Based Nanocarriers to Sequester Altered microRNAs in Cardiac Dysfunction

  • Postigo, Alejandro
  • Hernández-Bellido, Natalia
  • Sánchez-Barat, Marcos
  • García-Mendívil, Laura
  • Pueyo, Esther
  • del Barrio, Jesús
  • Hernández-Ainsa, Silvia
  • Ordovás, Laura
MicroRNAs (miRs) play a critical role in modulating gene expression across biological processes, including cardiac aging and disease. As such, miRs have demonstrated therapeutic potential in several cardiac conditions. Efficient delivery of miR therapies to cardiac tissue is crucial for effective gene therapy and DNA‐based nanocarriers (DNCs), based on Watson‐Crick‐Franklin highly specific base‐pair recognition, have emerged as a promising, biocompatible alternative to viral‐based methods. Here, DNCs designed to modulate miR levels as a potential treatment for cardiac dysfunction are presented. Specifically, the DNCs target miR‐24‐2, which inhibits SERCA2 gene. In humans, the reduction of SERCA2 activity is a hallmark of heart failure and is altered in cardiac aging. The assembled DNCs bearing anti‐miR‐24‐2‐5p sequences effectively restore intracellular levels of SERCA2 in a HEK293 cell model. The DNCs proper assembly is thoroughly verified, while their stability and miR‐capture ability are demonstrated in vitro. The DNCs exhibit successful internalization into HEK293 and modest uptake into human cardiomyocytes. SERCA2 restoration by DNCs is significantly influenced by the miR‐capture sequence layout, underscoring the importance of precise design for optimal biological outcomes. This study highlights the potential of DNCs in cardiac therapies, a previously unexplored avenue for addressing cardiac dysfunction.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A simple blood biomarker based on gene expression describes cardiovascular health-related biological age

  • Hernández-Bellido, Natalia
  • Hernández-Vicente, Adrián
  • García-Mendívil, Laura
  • Ramos-Marquès, Estel
  • Hernando, David
  • Cebollada, Alberto
  • Köhler, Ralf
  • Garatachea, Nuria
  • Pueyo, Esther
  • Ordovás, Laura
Abstract The need to monitor the aging process as a risk factor for disease and mortality beyond chronological age (CA) has led to numerous investigations into the estimation of the biological age (BA) of individuals. However, the accuracy of BA estimation tools is often judged by their ability to approximate CA, questioning their value in capturing the variance in health status and thus correctly estimating BA. Their biological relevance is often assessed in relation to health outcomes or mortality, underexploiting their potential for real-time monitoring of BA. Furthermore, their complexity may limit their clinical translation to large populations. Here, we describe the gene expression-based age monitoring Clock (GamC), a simple biomarker of aging (BOA), and characterize its biological relevance with synchronous cardiovascular (CV) health-related functional data. GamC is calculated from the expression levels of three genes consistently dysregulated with age in blood (ABLIM1, CCR7, and LEF1). GamC shows moderate but reliable association with CA in three independent cohorts, supported by transcriptome-wide changes. It demonstrates specialized biological meaning, as it specifically describes current physical activity levels, but poorly correlates with autonomic nervous system function, both age-related factors associated with CV health. Finally, it expresses BA monitoring capacity by modestly responding to an effective exercise-based intervention in centenarians. In conclusion, GamC is proposed as a simple and affordable candidate BOA for reporting the individuals’ current CV health-related BA, thus promoting its broad translation and application into measures aimed at promoting healthy aging in relation to CV health, the leading cause of death worldwide.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Nanotechnology-driven heart targeting to fulfil the potential of cardiac microRNA therapies

  • Hernández-Bellido, Natalia
  • Hernández-Ainsa, Silvia
  • Köhler, Ralf
  • Ordovás, Laura
MicroRNAs play a crucial role in regulating gene expression in most biological processes, including cardiac disease, regeneration and aging. They are therefore an attractive and novel therapeutic option, and extensive research in small animal models has demonstrated this potential in the heart. While the therapeutic outcomes obtained in large animal models are also promising, far fewer studies have been conducted in this species. Even fewer microRNA therapeutics have reached clinical trials, only CDR132L and MRG-110. This highlights a bottleneck in their development primarily associated with challenges in their in vivo delivery, specifically due to their limited stability and ability to penetrate the heart tissue. This review aims to describe the current state of development of cardiac microRNA therapies in relation to these challenges and to provide a comparative overview of the progress made in overcoming them. A special focus is set on the application of pharmaceutical nanotechnology and the development of targeted delivery strategies to the heart. These approaches have been tested primarily in small animal models and have shown to improve the cardiac penetration, accumulation and/or stability and of microRNAs and, therefore, their therapeutic efficacy compared to naked delivery. Notably, the latter is typically the method of choice in late preclinical research and early clinical trials. Consequently, targeted microRNA nanotherapies could be pivotal in overcoming the current bottleneck and realizing the therapeutic potential of microRNAs in the heart. In conclusion, this review offers an outlook of the future applicability of microRNA therapies leveraging the latest advances in non-viral targeted delivery with nanocarriers.